Conference
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL)
Authors
Le LH; Hirte HW; Hotte SJ; Maclean M; Iacobucci A; Corey A; Fox NL; Oza AM
Volume
22
Pagination
pp. 2533-2533
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
July 15, 2004
DOI
10.1200/jco.2004.22.90140.2533
Conference proceedings
Journal of Clinical Oncology
Issue
14_suppl
ISSN
0732-183X